{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:48:48Z","timestamp":1772160528394,"version":"3.50.1"},"reference-count":15,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2011,4,6]],"date-time":"2011-04-06T00:00:00Z","timestamp":1302048000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Background\u2002<\/jats:bold>\n                    Only a few, small double\u2010blind clinical trials have been reported for the treatment of vitiligo. Narrowband\u2010ultraviolet B (NB\u2010UVB) is an established form of treatment for this condition. Tacrolimus ointment is assumed to have an effect in some patients.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objectives\u2002<\/jats:bold>\n                    To assess the additive effect of tacrolimus ointment (0.1%) once daily in vitiligo patients treated with NB\u2010UVB.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods\u2002<\/jats:bold>\n                    In a randomized double\u2010blind trial, patients with stable symmetrical vitiligo were treated half\u2010side with tacrolimus ointment (0.1%) and half\u2010side with placebo ointment. Whole body NB\u2010UVB was given twice or thrice weekly for at least 3\u2003months. As a morphometric device, Visitrak\n                    <jats:sup>TM<\/jats:sup>\n                    was used to measure the area of the vitiligo target lesions.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results\u2002<\/jats:bold>\n                    Of 40 patients, 27 had a better effect on the tacrolimus side. The degree of improvement was significantly better on the tacrolimus side (\n                    <jats:italic>P\u2003<\/jats:italic>\n                    =\u20030.005). The median reduction in the target lesion areas was 42.1% on the tacrolimus side and 29% on the placebo side. There was a correlation between the effect and the number of topical tacrolimus applications (\n                    <jats:italic>P\u2003<\/jats:italic>\n                    =\u20030.044), but there was no correlation with the number of UV treatments given; neither any significance of gender, age, skin type, duration of disease, familial occurrence of vitiligo nor presence of other autoimmune disease or atopy was observed. We found a significant reduction in the patients\u2019 subjective disease impact during the treatment period (\n                    <jats:italic>P\u2003<\/jats:italic>\n                    &lt;\u20030.001).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion\u2002<\/jats:bold>\n                    According to this study, the combination of NB\u2010UVB and tacrolimus ointment (0.1%) is more effective than UV treatment alone in patients with vitiligo. The effect is tacrolimus total dose\u2010dependent.\n                  <\/jats:p>","DOI":"10.1111\/j.1468-3083.2011.04002.x","type":"journal-article","created":{"date-parts":[[2011,4,6]],"date-time":"2011-04-06T00:45:28Z","timestamp":1302050728000},"page":"1440-1443","source":"Crossref","is-referenced-by-count":59,"title":["Treatment of vitiligo with narrowband\u2010UVB (TL01) combined with tacrolimus ointment (0.1%) vs. placebo ointment, a randomized right\/left double\u2010blind comparative study"],"prefix":"10.1111","volume":"25","author":[{"given":"E.J.","family":"Nordal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.E.","family":"Guleng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.R.","family":"R\u00f6nnevig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,4,6]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.12.1532"},{"key":"e_1_2_6_3_2","first-page":"1381","article-title":"Psoralen and ultraviolet A and narrow\u2010band ultraviolet B in inducing stability in vitiligo, assessed by vitiligo disease activity score: an open prospective comparative study","volume":"21","author":"Bhatnagar A","year":"2007","journal-title":"JEADV"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2007.06280.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.7.927"},{"key":"e_1_2_6_6_2","first-page":"269","article-title":"Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo","volume":"20","author":"Kumaran MS","year":"2006","journal-title":"JEADV"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.126250"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.12.031"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.5.581"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2004.30058.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(00)90133-6"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.6.677"},{"key":"e_1_2_6_13_2","first-page":"558","article-title":"The efficacy of excimer laser (308\u2003nm) for vitiligo at different body sites","volume":"20","author":"Hofer A","year":"2006","journal-title":"JEADV"},{"key":"e_1_2_6_14_2","first-page":"891","article-title":"Narrowband UVB therapy for vitiligo: does the repigmentation last?","volume":"21","author":"Sitek JC","year":"2007","journal-title":"JEADV"},{"key":"e_1_2_6_15_2","first-page":"663","article-title":"Review of the potential photo\u2010cocarcinogenecity of topical calcineurin inhibitors","volume":"19","author":"Ring J","year":"2005","journal-title":"JEADV"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000057881"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2011.04002.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2011.04002.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T23:42:24Z","timestamp":1697326944000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2011.04002.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,6]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["10.1111\/j.1468-3083.2011.04002.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04002.x","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.13437046.14811180","asserted-by":"object"}]},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,6]]}}}